Abstract | OBJECTIVE: To report the results of a phase I trial to evaluate the safety and efficacy of atovaquone for the treatment of ocular toxoplasmosis in immunocompetent patients. DESIGN: Open label, nonrandomized, prospective, clinical trial. PARTICIPANTS: Seventeen immunocompetent patients between the ages of 18 and 75 years with clinical and serologic evidence of ocular toxoplasmosis participated. INTERVENTION: MAIN OUTCOME MEASURES: RESULTS: Average follow-up was 10 months. Most patients experienced no adverse treatment effects. When present, side effects were usually mild and included rash, pruritus, headache, and nausea. With the exception of one patient, who discontinued treatment at 6 weeks secondary to persistent epigastric discomfort, all patients completed the 12 weeks of therapy. All patients had a favorable response to treatment that began within 1 to 3 weeks. Visual acuity was stabilized or improved in all patients. Median initial visual acuity was 20/200 and median final visual acuity was 20/25. In general, atovaquone was well tolerated. CONCLUSIONS:
|
Authors | P A Pearson, A R Piracha, H A Sen, G J Jaffe |
Journal | Ophthalmology
(Ophthalmology)
Vol. 106
Issue 1
Pg. 148-53
(Jan 1999)
ISSN: 0161-6420 [Print] United States |
PMID | 9917796
(Publication Type: Case Reports, Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiprotozoal Agents
- Naphthoquinones
- Atovaquone
|
Topics |
- Adolescent
- Adult
- Aged
- Antiprotozoal Agents
(adverse effects, therapeutic use)
- Atovaquone
- Chorioretinitis
(drug therapy, parasitology, pathology)
- Drug Evaluation
- Female
- Follow-Up Studies
- Fundus Oculi
- Humans
- Immunocompetence
- Middle Aged
- Naphthoquinones
(adverse effects, therapeutic use)
- Prospective Studies
- Safety
- Toxoplasmosis, Ocular
(drug therapy, parasitology, pathology)
- Treatment Outcome
- Visual Acuity
|